Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints and surrounding structures, often leading to systemic skeletal complications and an increased risk of fragility fractures. Treatment typically involves steroids-based therapy, mostly glucocorticoids, which are known to enhance bone resorption and reduce bone strength. Radiofrequency Echographic Multi-Spectrometry (REMS) is a non-ionizing technology that represents the alternative to the current standard Dual X-Ray Absorptiometry (DXA) and allows to predict the imminent (within 5 years) fracture risk (FR). Therefore, the aim of the present study is to assess the REMS-based 5-years FR in a cohort of patients with RA and PA.
Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Contaldo;
2025
Abstract
Background/Purpose: Autoimmune arthritis, including Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PA), are among the most common forms of inflammatory joint diseases. These conditions affect joints and surrounding structures, often leading to systemic skeletal complications and an increased risk of fragility fractures. Treatment typically involves steroids-based therapy, mostly glucocorticoids, which are known to enhance bone resorption and reduce bone strength. Radiofrequency Echographic Multi-Spectrometry (REMS) is a non-ionizing technology that represents the alternative to the current standard Dual X-Ray Absorptiometry (DXA) and allows to predict the imminent (within 5 years) fracture risk (FR). Therefore, the aim of the present study is to assess the REMS-based 5-years FR in a cohort of patients with RA and PA.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
